90 related articles for article (PubMed ID: 23507600)
41. Temsirolimus in overtreated metastatic renal cancer with subsequent use of sunitinib: A case report.
Jurado JM; Zarcos I; Delgado M; Blancas I; Legerén M; García-Puche JL
Oncol Lett; 2013 Apr; 5(4):1382-1384. PubMed ID: 23599798
[TBL] [Abstract][Full Text] [Related]
42. Safety, efficacy, and tolerability of systemic therapies in male breast cancer: are there sex-specific differences?
Yadav S; Giridhar KV; Taraba J; Leon-Ferre R; Ruddy KJ
Expert Opin Drug Saf; 2020 Aug; 19(8):923-926. PubMed ID: 32716212
[No Abstract] [Full Text] [Related]
43. Breast cancer and the environment: what is left to learn?: A Countercurrents Series.
Narod SA
Curr Oncol; 2013 Feb; 20(1):8-9. PubMed ID: 23443916
[No Abstract] [Full Text] [Related]
44. Left Alone After a Rare Cancer Diagnosis.
Coutinho M
Narrat Inq Bioeth; 2020; 10(3):188-190. PubMed ID: 33583842
[No Abstract] [Full Text] [Related]
45. Expression of phosphorylated eIF4E-binding protein 1, but not of eIF4E itself, predicts survival in male breast cancer.
Millican-Slater RA; Sayers CD; Hanby AM; Hughes TA
Br J Cancer; 2016 Jul; 115(3):339-45. PubMed ID: 27280636
[TBL] [Abstract][Full Text] [Related]
46. mTOR pathway inhibition in renal cell carcinoma.
Pinto Marín A; Redondo Sánchez A; Espinosa Arranz E; Zamora Auñón P; Castelo Fernández B; González Barón M
Urol Oncol; 2012; 30(4):356-61. PubMed ID: 20207176
[TBL] [Abstract][Full Text] [Related]
47. Targeted therapy for renal cell cancer: current perspectives.
van der Veldt AA; Haanen JB; van den Eertwegh AJ; Boven E
Discov Med; 2010 Nov; 10(54):394-405. PubMed ID: 21122471
[TBL] [Abstract][Full Text] [Related]
48. Future perspectives for mTOR inhibitors in renal cell cancer treatment.
Czarnecka AM; Kornakiewicz A; Lian F; Szczylik C
Future Oncol; 2015; 11(5):801-17. PubMed ID: 25757683
[TBL] [Abstract][Full Text] [Related]
49. [A case of male breast cancer for which mTOR inhibitor was effective with advanced renal cancer].
Katayama K; Yamagishi J; Kashiwagi B
Gan To Kagaku Ryoho; 2013 Mar; 40(3):365-9. PubMed ID: 23507600
[TBL] [Abstract][Full Text] [Related]
50. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
51. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?
Fedele P; Calvani N; Marino A; Orlando L; Schiavone P; Quaranta A; Cinieri S
Crit Rev Oncol Hematol; 2012 Nov; 84(2):243-51. PubMed ID: 22494933
[TBL] [Abstract][Full Text] [Related]
52.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
